the CDR antibodies partially recovered CB immunoreactivity, suggesting a transient structural change in CB calcium-binding site. We discovered that CDR2 and CB coimmunoprecipitate. Furthermore, the expression levels of voltage-gated calcium channel Cav2.1, protein kinase C gamma and calcium-dependent protease, calpain-2, were increased after CDR antibody internalization. Inhibition of these signaling pathways prevented or attenuated CDR antibody-induced CB and L7/Pcp-2 immunoreactivity loss, morphological changes and increased protein expression. These results signify that CDR antibody internalization causes dysregulation of cell calcium homeostasis. Hence, drugs that modulate these events may represent novel neuroprotective therapies that limit the damaging effects of CDR antibodies and prevent PC neurodegeneration. 
Introduction
Paraneoplastic cerebellar degeneration (PCD), caused by Purkinje cell (PC) death in the cerebellum, is a paraneoplastic neurological disorder with severe pancerebellar symptoms, such as ataxia, nystagmus, and dysarthria [72] . Cross-reactivity of onconeuronal Yo antibodies (Yo Abs) and T cells with antigens in the tumor tissue and cerebellum induce PCD [63] . Yo Abs bind to the cytoplasmic antigen of cerebellar degeneration-related protein 2 (CDR2, 50 kDa, RefSeq NM_001802.1) and 2-like (CDR2L, 62 kDa, RefSeq NM_014603.2) and are found in the serum and cerebrospinal fluid of patients with remote, non-metastatic ovarian and breast cancers [7, 22, 72] .
Brain, normal ovary tissue, and tumor tissue express CDR2 protein [15, 30, 70] . CDR2 interacts with proteins involved in signal transduction and gene transcription such as: cell cycle-related proteins; PKN, a fatty acid-activated serine/threonine protein kinase; and c-myc [48, 49, 54, 55, 66] . CDR2L has ~50 % sequence identity with CDR2, but is not expressed in PCD tumor tissue [15] . In the cerebellum, both CDR2 and CDR2L proteins are present in the cytoplasm and proximal dendrites of PCs, but their functions are unknown [15, 49, 52] .
The PCs are the sole projection neurons in the cerebellum and therefore proper morphological as well as physiological integrity of the PC dendrites is essential for cerebellar function [25, 67] . Optimal intracellular Ca 2+ levels and Ca 2+ flux via cytoplasmic Ca 2+ -binding protein calbindin D 28K (CB) and the GoLoco domain protein, Purkinje cell-specific protein-2 (L7/Pcp-2), are essential for cellular and molecular mechanisms involved in neurotransmitter release, ion channel permeability, enzyme activity, and gene transcription [6, 24, 39, 57] . With its four Ca 2+ -binding sites, CB is a Ca 2+ buffer and sensor; it regulates fast Ca 2+ influx by Ca 2+ binding [57] and is considered as a PC survival marker [28, 38] . L7/Pcp-2 modulates P/Q-type voltage-gated calcium channels' (VGCC) function, whose dysfunction is implicated in ataxia [27, 39, 69] . Factors that modulate or disrupt CB and L7/Pcp-2 are expected to exert powerful physiological and pathological effects on PCs and are listed in Table S1 .
In the present study, an ex vivo model of rat cerebellar organotypic slice culture (cOTSC) was used to study the neuropathological mechanisms underlying the antibodymediated PCD and to identify potential intracellular treatment targets which are elaborated in Table S1 . Multiphoton imaging showed that CDR2 and CDR2L antibody internalization reduced the CB and L7/Pcp-2 immunoreactivity levels in PCs. This antibody-driven immunoreactivity loss was reduced by modifying the intracellular Ca 2+ transients and inhibiting the Ca 2+ -dependent protease calpain (Table 1) . These findings suggest that widespread consequences of Ca 2+ homeostasis dysregulation can induce morphological changes and fatal alterations in the cell signaling pathways, thereby causing neurodegeneration.
Materials and methods

Patients' sera
We used four female patients' sera that were antibody positive for CDR2 (hCDR2
), CDR2L (hCDR2L
) or both CDR2 and CDR2L (hCDR2/2L +(PS3/PS4) ) [22] and negative for P/Q-type VGCC (RIA; DLD Diagnostika, #RA006/12). Patient data are listed in Table S2 . The sera were collected before treatment took place and stored at −80 °C at the Paraneoplastic Neurological Diseases Biobank (#484) with the approval of the Regional Committee for Medical and Health Research Ethics in Western Norway, Diagnostic markers of cancer (188.05). As control serum, we pooled samples from 100 healthy blood donors without any known autoimmune disease (non-hCDR).
Cerebellar organotypic slice culture (cOTSC)
All procedures were performed according to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals Norway (FOTS 20135149/20113133) . To prepare cOTSC, we used 152 Wistar Hannover GLAST rat pups (in-house breeding colony), age P10-P15. Following anesthesia and decapitation, we transferred the cerebellum into ice-cold EBSS solution (Gibco, #24010043) containing 0.5 % D-glucose (Sigma, #G8769) and 10 mM HEPES (Gibco, #15630056). Four to five cerebellar parasagittal slices (400 μm thick) were cut on NVSLM1 motorized advance vibroslice (WPI) and transferred individually onto 0.4 μm pore size membranes (Millicell, Millipore, # PICMO1250). Slices were maintained in 24-well plates at the air/culture media interface consisting of 30 % advanced DMEM/F12 solution (Gibco, #126340010), 20 % MEM solution (Gibco, #41090028), 25 % EBSS solution, 25 % heat-inactivated horse serum (Sigma, #H1138), 1 mM l-glutamine (Gibco, #35050038), 5 mg/mL d-glucose, and 2 % B-27 serum-free supplement (Gibco, #17504044), and incubated with 5 % CO 2 at 35 °C (Fig. 1a) . The culture medium was removed and replaced 24 h post-slicing (100 %) and then every 2nd day (75 %). The slices recovered for 7 days before treatment.
Antibody-mediated PCD model: patients' sera (hCDR) and polyclonal affinity-purified rabbit antibodies (rCDR) hCDR and rCDR were heat inactivated (56 °C, 30 min) to destroy complement factors prior to treatment to obtain neutral IgG antibody assays and added at various concentrations to the cOTSC media for 2-6 days (Fig. 1b) . We used human sera hCDR2 + , hCDR2L + , and hCDR2/2L + , non-hCDR at dilutions of 1:250, 1:500, and 1:1000, and affinity-purified polyclonal rabbit antibody rCDR2 (Sigma, #HPA023870), rCDR2L (Sigma, #HPA022015), or both (1:1 mixture) and rIgG (Millipore, #12370) in total concentrations of 20, 40, 125, or 400 ng/mL. Each independent experiment (n ≥ 3) included positive and negative controls to avoid variations in immunoreactivity to the applied hCDR and rCDR between each experiment.
Neuropharmacology
The following drugs were used: MDL28170 a potent, selective inhibitor of calpain (K i = 10 nM; Tocris, #1146); CNQX an AMPA receptor antagonist (IC 50 = 1-2 μM; Tocris, #1045); ω-agatoxin a selective and reversible blocker of Cav2.1 (P/Q-type VGCC) (Alomone, #A-530); K252a a non-selective protein kinase inhibitor that inhibits PKC (IC 50 = 32.9 nM; Tocris, #1683); U0126 a selective non-competitive inhibitor of MEK-1 and MEK-2 (IC 50 = 60-70 nM; Tocris, #1144).
Primary antibodies
The antibodies used in immunohistochemical (IHC), Western blot (WB), and immunoprecipitation (IP) analyses are detailed in Table S3 .
Immunohistochemistry cOTSC sections
After treatment, cOTSC were washed with pre-warmed 0.1 M PBS (1xPBS; Gibco, #70013016) and fixed (4 % paraformaldehyde (PFA)/0.5 % sucrose in PBS, pH 7.2; 4 h, 4 °C). Slices were quenched with PBS/50 mM NH 4 Cl (PBS N ), permeabilized with PBS N /1 % Triton X-100 (60 min, 22 °C), rinsed (3 × 5 min) with PBS N , and incubated in primary Ab against calbindin D 28K , caspase-3, or L7/Pcp-2 for 2 days at 4 °C in PBS N containing 5 % bovine serum albumin (BSA; Sigma, #A2153), 0.2 % Triton X-100 (Sigma, #T9284), and 100 μM glycine (Sigma, #G7126). The slices were washed (3 × 5 min) with PBS N and incubated with 2nd Ab (Alexa Fluor ® 488/594 Donkey Anti-Mouse and/or Donkey Anti-Rabbit IgG (H + L), 1:500; Molecular Probes, #A21202, #A21203, #A21204, or # A21207) for 2 days at 4 °C in PBS N /2.5 % BSA. Slices were rinsed (3 × 5 min) with PBS N and mounted with PromoFluor Antifade Reagent (Promokine, #PK-PF-AFR1). The slices from each experiment were stained simultaneously to minimize variations in immunoreactivity of primary and 2nd Ab solution within the investigated groups.
Cryostat sections
Anesthetized adult female rats were transcardially perfused with ice-cold 4 % PFA-PBS. The brains were post-fixed (24 h, 4 °C), incubated in 18 % sucrose-PBS (72 h, 4 °C), snap-frozen, and cut on a cryostat into 8 μm parasagittal sections. Sections were air dried (30 min, 22 °C), blocked in PBS/0.2 % BSA/1 % Triton X-100 (PBS B , 2 h, 22 °C), incubated in patient serum (PBS B /patient serum, overnight, 4 °C, 1:2000), rinsed (3 × 5 min) with PBS, incubated with 2nd Ab (PBS B /Alexa Fluor ® 488 Goat Anti-Human IgG (H + L), 1:500, # A11013, Molecular Probes, 2 h, 22 °C), rinsed (3 × 5 min) with PBS, and mounted with ProlongGold Antifade Reagent (Invitrogen, #P36931). Slices were scanned with a DM6000 CFS-TCS SP5 confocal microscope (Leica).
Paraffin-embedded sections
Six days after hCDR2/2L and non-hCDR internalization, slices were fixed (4 % PFA), embedded in paraffin, sliced into 4 µm thick sections, and stained with hematoxylin and a b 
Western blot analysis
The treated cOTSC were washed with pre-warmed 1xPBS (pH 7.4) and sonicated in ice-cold lysis buffer (in mM: 50 Tris-HCl (pH 7.5), 150 KCl, 1 DTT, 1 PMFS, 0.1 % NP40, 1 % SDS, and complete protease inhibitor cocktail (Roche, #1187380001)). The lysates (40 μg) were subjected to gradient SDS-PAGE under reducing conditions (15-4 % Tris TGX gels; Bio-Rad, #456-1086), transferred onto PVDF membrane (0.2 μm pore size; Bio-Rad, #162-0177) and incubated overnight (4 °C) with anti-calbindin D 28K , anti-calpain-1, anti-calpain-2, anti-Cav2.1, anti-PKCγ, and anti-β-tubulin. The blots were developed using horseradish peroxidase-conjugated 2nd Ab (polyclonal Swine Anti-Rabbit IgG-HRP, Dako, #P0217; Goat Anti-Mouse IgG-HRP, Santa Cruz Biotechnology Inc., #SC-2500; 90 min, 22 °C) and the Pierce ECL chemiluminescence system (Thermo Fisher Scientific Inc., #3210634075). Semi-quantitative densitometry analysis was performed (Bio-Rad, Quantity One 4.6.6). For each sample, the protein level was normalized to β-tubulin and expressed relative to untreated naive control, set at 1 (arbitrary units).
Protein complex immunoprecipitation (Co-IP)
Co-IP was performed with rat cerebellar tissue. The tissue was homogenized by 10-15 strokes in a Dounce-type glass homogenizer (buffer in mM: 20 Tris-HCl (pH 7.4), 137 NaCl, 10 % glycerol, 1 EDTA, 1 PMSF, 1 DTT, 1 % NP-40, protease inhibitors). Homogenates were centrifuged (13,000g, 4 °C, 10 min) and the supernatants were used for immunoprecipitation after pre-clearing with protein G magnetic beads (1 h, 4 °C; Millipore, # LSKMAGG02). The supernatants were incubated with 2 μg/mL of specific Ab with constant agitation (overnight, 4 °C). A further 40 μL of fresh protein G magnetic beads was added and incubated for 1 h at 4 °C. The beads were washed three times (IP buffer in mM: 50 Tris-HCl (pH 7.4), 150 NaCl, 1 EDTA, 1 PMSF, 1 DTT, 0.1 % NP-40, protease inhibitors) and incubated with 100 mM dithiothreitol and 2× Laemmli sample buffer (5 min, 95 °C). Eluted proteins were resolved by SDS-PAGE. We immunoprecipitated against: anti-CDR2, anti-CDR2L, anti-Cav2.1, and anti-calbindin D 28k (2 μg).
Data analysis and statistics
Data analysis and calculations were performed using the software Excel 2003 and Graph Pad Prism 4.0. Data are presented as mean ± SEM, and statistical significance was determined using the non-parametric two-tailed paired Mann-Whitney's U test. The level of significance is indicated with asterisks: *p < 0.05; **p < 0.01; ***p < 0.001.
Results
Calbindin D 28K (CB) function is modified by hCDR and rCDR antibodies
We investigated four female patients' sera that were positive for CDR2, CDR2L, or both CDR2/2L and negative for P/Q-type VGCC (Table S2) . Cerebellum cryostat sections incubated with those human patients' sera (hCDR; 1:2000) confirmed that hCDRs bound to PCs. hCDR2/2L +(PS3/ PS4) showed stronger PC binding than hCDR2 +(PS1) and hCDR2L +(PS2) (Fig. 2a) . To evaluate the pathological effects of hCDR internalization into PCs in the absence of the lymphatic system and blood-brain barrier, we applied the sera to cOTSC (Fig. 1a) . We collected samples at different time points and studied PC survival by counting CB-positive PCs in multiphoton micrographs (Fig. 1b, c) [28, 38] . To exclude Ab diffusion into dead PCs with permeable membranes, we performed control monoclonal anti-CB staining without Triton X-100 in the incubation buffers. We did not find false-positive CB immunoreactivity (data not shown). hCDR internalization significantly reduced the number of CB-positive PCs (CB + -PCs) over time (n E = 4; Fig. 2c, d ; Table 1 ). The remaining CB + -PCs showed reduced dendritic arborizations (Fig. 2b) . Within 48 h, CB + -PC loss was significantly higher in hCDR2L
+(PS1) (*p = 0.0373; Fig. 2c ), but did not differ between hCDR2/2L +(PS3) and hCDR2/2L +(PS1+PS2) and was most strongly pronounced in hCDR2/2L +(PS4) ( Fig. 2d ; Table 1 ). Compared to the non-hCDR control, more than 70 % of CB + -PCs were lost at day 6 of hCDR internalization (***p < 0.0001; Fig. 2c, d ; Table 1 ).
To elucidate whether the observed pathology was induced by CDR antibodies, we treated the cOTSC with heat-inactivated affinity-purified polyclonal rabbit Abs against CDR2 (rCDR2 + ) and CDR2L (rCDR2L + ), or both (1:1 mixture, rCDR2/2L). We found that within 6 days both rCDR2 and rCDR2L were internalized and led to extensive loss of CB staining (400 ng/mL; Fig. 3a, merged) . We observed three patterns of CB immunoreactivity modifications after rCDR treatment: (1) whole cell staining with neighboring cells unstained, (2) dendritic staining with only a weak remaining signal in the soma, and (3) soma staining with no dendritic staining (Fig. 3b) . The remaining CB + -PCs showed morphological alterations in their dendritic arborizations with a loss of tertiary branches (Fig. 3c) .
To verify the progression of rCDR-induced PCD-like pathology, samples were collected at different time points (n E = 4; 400 ng/mL; Fig. 3c, d) . We found no effect on the number of CB + -PCs in rIgG control. Meanwhile within 48 h, we observed that rCDR treatment caused a 50-60 % CB + -PCs loss. The CB + -PC loss under rCDR2/2L and rCDR2L was of similar magnitude, but significantly greater than in rCDR2 (n E = 4, *p = 0.0369; Fig. 3d ; Table 1 ). rCDR reduced CB + -PCs by ~80 % within 6 days (rCDR groups compared to rIgG + ***p < 0.0001; Fig. 3d ; Table 1 ). The progression of the antibody-driven loss of CB in the first 48 h was similar in rCDR2 and rCDR2L compared to hCDR2 +(PS1) and hCDR2L
( Table 1) . To study antibody level effects, we tested four rCDR concentrations (ng/mL): 400, 125, 40, and 20 (n E = 3, 4 days). We found a reduction of CB + -PCs by ~80 % (400 and 125 ng/mL), 60 % (40 ng/mL), and 40 % (20 ng/mL) compared to rIgG control (***p < 0.0001; Fig. 3e ) with no difference between rCDR2 and rCDR2L.
The Western blot analysis of rCDR-treated cOTSC lysates (6 days, 125 ng/mL) showed no effect on CB protein concentration compared to untreated naive control (n E = 10; Fig. 3f, g ). It is therefore likely that the reduced CB immunoreactivity is caused by structural modifications of the CB Ca 2+ -binding site or misfolding of the protein itself [11, 50] . To investigate this hypothesis, we replaced the rCDR-containing media (125 ng/mL, 6 days) with non-CDR media (Fig. 1b, washout, 7 days) . The number of CB + -PCs in rIgG control was not affected by washout or by time (Fig. 3h, i) . We found that the washout of rCDR improved the CB + -PC count in rCDR2L and rCDR2/2L -treated cOTSC within 48 h (D2wo) (rCDR2: p = 0.1383, rCDR2L: **p = 0.0018, rCDR2/2L: **p = 0.0010; Fig. 3i ). All rCDR groups showed substantial recovery of CB + -PCs at day 7 after washout (***p < 0.0001; Fig. 3h To analyze whether CDR proteins and CB interact at physiological expression levels, we assayed by reciprocal co-immunoprecipitation (Co-IP) CDR2, CDR2L, and CB proteins from cerebellar lysates. As shown in Fig. 4a , b, CB and CDR2 specifically Co-IPed, indicating endogenous CDR2-CB complex in PCs. Interestingly, CDR2L did not form any complex with CB (anti-CDR2L from three sources), but showed strong CDR2 Co-IP (Fig. 4a, c) . These Co-IP results suggest that CDR2 antibody can substantially influence CB function by binding to an interacting protein.
Although CB immunoreactivity was reduced after hCDR and rCDR internalization, the micrographs in Fig. 3a showed no cell loss. HE staining of hCDR2/2L
-treated cOTSC (1 μL/mL, 6 days) showed normal cytoarchitecture and no distinct loss of PCs (Fig. S1a) . Furthermore, staining for the apoptotic marker of active cleaved caspase-3 in rCDR2/2L-treated cOTSC (100 ng/mL, 6 days) showed small scattered cleaved caspase-3-positive apoptotic cells which did not co-localize with CB + -PCs (Fig. S1b) . This caspase-3 staining profile was not different from the rIgG control.
GoLoco domain protein L7/Pcp-2 is affected by hCDR and rCDR antibodies PCs express GoLoco domain protein L7/Pcp-2, which interacts with Gα o and Gα i proteins and thereby modulate the P/Q-type VGCC (Cav2.1) functions in a concentration-dependent manner [39] . The P/Q-type is the major VGCC in PCs and linked to ataxia pathogenesis [27, 69] . To evaluate whether L7/Pcp-2 is influenced by CDR internalization, we stained hCDR-and rCDR-treated cOTSC against L7/Pcp-2. The L7/Pcp-2 positive (L7/Pcp-2 + ) PC loss was similar to the observed CB + -PC loss ( Fig. S2 ; Table 1 ). Both hCDR (1 μL/mL) and rCDR (100 ng/mL) induced L7/Pcp-2 + -PC loss of more than 65 % (6 days, hCDR n E = 3; rCDR n E = 4; compared to rIgG control ***p < 0.0001; Fig. S2a-d ; Table 1 ).
This suggests that another important Ca 2+ homeostasis regulator is affected by CDR antibody internalization.
VGCC Cav2.1 is up-regulated by hCDR and rCDR antibodies
To confirm the suggested interaction of L7/Pcp-2 and Cav2.1, we performed Co-IPs on rat cerebellum extract and confirmed the protein complex (Fig. 5a) . As a consequence of this interaction, the CDR antibody-induced loss of L7/Pcp-2 might influence the VGCC protein expression. To test whether VGCCs are affected by CDR internalization, we performed Western blot analysis of rCDRtreated cOTSC. We found that rCDR internalization increased the protein expression of Cav2.1 by more than twofold (100 ng/mL, 6 days, all groups compared to rIgG controls, ***p < 0.0001; Fig. 5b, c) and co-treatment with VGCC antagonist ω-agatoxin (150 nM) blocked this effect ( Fig. 5g, h; # p < 0.005; n E = 6). ω-agatoxin co-treatment averted CB + -and L7/Pcp-2 + -PC loss ( Fig. 5d-f ). The rescue of CB and L7/Pcp-2 immunoreactivity was most strongly pronounced in rCDR2/2L + /ω-agatoxin co-treated cOTSC (***p < 0.0001, 6 days; n E = 5; Fig. 5e, f Inactivation of VGCC by blocking AMPA receptormediated synaptic depolarization with AMPA receptor antagonist CNQX revealed a similar rescue of CB + -and L7/Pcp-2 + -PC loss ( Fig. 6a-e ; Table 1 ). We found that co-treatment of hCDR2/2L +(PS3) (1 μL/ mL) with CNQX minimized the CB + -PC loss significantly in a concentration-dependent manner (CNQX: 44 ± 8 % (5 μM), 24 ± 8 % (10 μM), 14 ± 6 % (25 μM); ; ***p < 0.0001; 6 days; n E = 4; Fig. 6b , c; Table 1 ). The CDR-specific effects of CNQX (10 μM) were also tested with rCDR2 and rCDR2L (100 ng/mL, We found different expression patterns of CB immunoreactivity and PC morphology modifications for rCDR2 b, rCDR2L, and rCDR2/2L compared to rIgG control (c); scale bars 40 μm. The CB immunoreactivity loss, studied 2, 4, and 6 days of rCDR internalization by stereological counting of CB + cells/mm 3 , was time-(d) and concentration-(e) dependent (time: n E = 4; concentration: n E = 3). f, g Western blot analysis of rCDR-treated cOTSC lysate (125 ng/ mL, D6) showed no difference in CB protein levels to rIgG controls (n E = 10). h CB + -PC immunoreactivity loss at day 6 of rCDR internalization was partially rescued 7 days (D7wo) post-rCDR washout (scale bars 40 μm), but did not reach control level and plateaued between washout days 4 and 7 (n E = 3) (i). Data in mean ± SEM. Non-parametric two-tailed paired Mann-Whitney's U test. *p < 0.05; **p < 0.01; ***p < 0.001. Table 1 : CDR-Ab effects in percentage 6 days). rCDR/CNQX co-treatment partially rescued CB + -PCs (***p = 0.0001; n E = 6; Fig. 6d ; Table 1 ), with better rescue in rCDR2L/CNQX (63 %) than rCDR2/CNQX (38 %) (**p = 0.0054). The L7/Pcp-2 + -PC count in cotreated rCDR2 or rCDR2L cOTSC with 10 μM CNQX showed reduction of L7/Pcp-2 + -PC loss to 48 ± 3 % (rCDR2/CNQX) and 27 ± 5 % (rCDR2L/CNQX), respectively (***p < 0.0001; 6 days; n E = 4; Fig. 6e ; Table 1 ). The CNQX co-treatment was more beneficial for rCDR2L than for rCDR2, as seen with CB staining (L7/Pcp-2 + -PC rescue: 30 % (CDR2) vs. 60 % (CDR2L), **p = 0.0011). The number of CB + -and L7/Pcp-2 + -PCs in the rIgG control was not affected by the AMPA receptor antagonist.
Taken together, these data show that reducing Ca 2+ influx through VGCC mitigates the CDR antibody-induced pathology by lowering intracellular Ca 2+ levels.
PKCγ is up-regulated by CDR2 and CDR2/2L antibodies
The postsynaptic Ca 2+ transient can be modulated by inhibition of Ca 2+ -activated phospholipid-dependent protein kinase C (PKC) activity to prevent AMPA receptormediated synaptic depolarization [19, 73] . PKC is associated with apoptosis in cerebellar ischemia and stroke [8] . Missense mutations in PKCγ gene cause spinocerebellar ataxia type 14 [58, 60] . We found that 6 days of rCDR2 and rCDR2/2L internalization significantly increased PKCγ protein expression (rCDR2: 1.43 ± 0.12, **p = 0.0079; rCDR2/2L: 1.62 ± 0.29, *p = 0.0250; Fig. 7a, b) , but not rCDR2L (1.23 ± 0.18, p = 0.1810; Fig. 7b ). Therefore, we co-administrated 50 nM K252a to inhibit PKC activity during CDR internalizations. Blocking PKC activity with K252a prevented CDR antibodyinduced CB
[1 μL/ mL]; 6 days; ***p < 0.0001; n E = 4; and rCDR [125 ng/ mL]; ***p < 0.0001; 6 days; n E = 4; Fig. 7c-f ; Table 1 ) and blocked the increased PKCγ protein expression caused by rCDR2 and rCDR2/2L internalization ( Fig. 7g,  h; # p < 0.003; n E = 6). rCDR2L internalization had no effect on PKCγ protein expression, while CB + -and L7/ Pcp-2 + -PC loss was rescued by K252a co-treatment in the rCDR2L group. The antagonist had no effect on the CB + -or L7/Pcp-2 + count or PKCγ protein expression in the rIgG and untreated naive control.
The results show that the CDR antibody-mediated pathology can be attenuated in the presence of VGCC, AMPA receptor, and PKC signaling inhibition.
Ca
2+ -dependent protease calpain-2 is activated by CDR antibody internalization Changes in VGCC, AMPA receptor, and PKC signaling can lead to elevated intracellular Ca 2+ levels and induce Ca 2+ -dependent proteases activity. To examine whether CDR internalization affects Ca 2+ -dependent proteases activity of calpain-1 and calpain-2, we performed Western blot analysis of rCDR-treated cOTSC lysates. Calpain-1 expression was not affected, but calpain-2 expression was significantly increased (rCDR2: 2.05 ± 0.14, ***p < 0.0001; rCDR2L: 1.72 ± 0.14, ***p = 0.0002; rCDR2/2L: 1.84 ± 0.19, **p = 0.0012; 125 ng/mL; 6 days; Fig. 8a-c) . We then investigated whether calpain-2 over-activation/-expression a b c could be antagonized by calpain-specific inhibitor MDL28170, a known neuroprotective substrate in ischemia and traumatic injury models [9, 36] . MDL28170 coapplication with hCDR2/2L +(PS3/PS4) (6 days) reduced the CB + -PC loss to ~45 %, as well as the CDR-induced pathology on the dendritic arborizations in the remaining PCs (n E = 6 for PS3 and n E = 4 for PS4; Fig. 8d , e; Table 1 ). We found no difference between the 10 (42 ± 9 %) and + (e) and L7/Pcp-2 + (f) cells/mm 3 supported the observed neuroprotective effect of ω-agatoxin during rCDR internalization for all tested groups (n E = 7). g Representative Western blot: Cav2.1 expression after rCDR/ω-agatoxin co-treatment; h ω-agatoxin co-treatment blocks the rCDR-induced increase in Cav2.1 expression (n E = 7). Data are mean ± SEM. Non-parametric two-tailed paired Mann-Whitney's U test. *p < 0.05; **p < 0.01; ***p < 0.001; # p < 0.005; -induced L7/Pcp-2 + -PC loss was partially rescued by 10 μM MDL28170 (***p < 0.0001; n E = 3; Fig. 8f ; Table 1 ). MDL28170 (10 μM) co-treatment of rCDR2, rCDR2L, and rCDR2/2L-treated cOTSC (125 ng/mL, 6 days) showed an improvement of the dendritic morphology and significant reduction of CB + -PC loss (***p < 0.0001; n E = 5; Fig. 8g ; Table 1 ). The increase of calpain-2 expression seen during CDR internalization was blocked by 10 μM MDL28170 (Fig. 8h, i; # p < 0.008; n E = 6). These data show that CDR internalization leads to an increase in intracellular unbound Ca 2+ to the millimolar range, which thereby activate the Ca 2+ -dependent protease calpain 2.
MAP kinase signaling is not affected by CDR antibody internalization
Activation of mitogen-activated protein (MAP) kinase signaling cascades are associated with PKC-dependent synaptic depression/declustering of glutamate receptors, inflammation, death receptor activation, apoptosis, and oxidative stress [12, 23, 35] . Co-treatment of cOTSC with hCDR2/2L + (1 μL/mL, 6 days) and MAP kinase inhibitor U0126 (5 μM) did not prevent the CB + -or L7/Pcp-2 + -PC immunoreactivity loss (CB: hCDR2/2L +(PS3) : 70 ± 10 vs. 68 ± 7 % (5 μM U0126); p = 0.4268; L7/Pcp-2: hCDR2/2L +(PS4) : 65 ± 3 vs. 64 ± 2 % (5 μM U0126), p = 0.5249; n E = 4; Fig. 8j ).
These data suggest that the MAP kinase signaling cascade is not involved in the CB or L7/Pcp-2 immunoreactivity reduction induced by hCDR2/2L.
Discussion
CDR antibodies, also known as onconeuronal Yo antibodies, have attracted increasing interest due to their suggested pathological role in the progressive loss of PCs seen in PCD after binding to CDR2 and CDR2L antigens [22, 31, 33, 70] . Because the mechanisms underlying PCD, in particular the effects of CDR antibodies, are largely unknown, we investigated whether they are internalized into PCs and how that affects PC physiology. : n E = 6; PS4: n E = 4) or rCDR-induced pathology (125 ng/mL, 10 μM, n E = 6) in a concentration-dependent manner and more beneficially for rCDR2L than rCDR2 (CB: **p = 0.0071; L7/Pcp-2: **p = 0.0011). Data are mean ± SEM. Non-parametric two-tailed paired Mann-Whitney's U test. *p < 0.05; **p < 0.01; ***p < 0.001; # p < 0.005; Table 1 : CDR antibody effects in percentage +(PS3) [4 μL/mL] d CB: n E = 4; e L7/Pcp-2: n E = 4; f rCDR2 and rCDR2L [125 ng/ mL] CB: n E = 6; L7/Pcp-2: n E = 6). g Representative Western blot: PKCγ expression after rCDR/K252a co-treatment. h K252a co-treatment reduces the rCDR-induced PKCγ expression rise in the rCDR2 and rCDR2/2L group (125 ng/mL; n E = 5) after K252a co-treatment. Investigated samples: 6 days of CDR internalization; data in mean ± SEM; non-parametric two-tailed paired Mann-Whitney's U test. *p < 0.05; **p < 0.01; ***p < 0.001; # p < 0.003; Table 1 : CDR antibody effects in percentage Fig. 8 Calpain-2 activity is increased by CDR-Ab internalization, but not MAP kinase. a Representative Western blot: calpain-1 and calpain-2 expression after rCDR internalization and MDL28170 co-treatment (h). b Bar plots show that calpain-1 expression is not affected, but c calpain-2 expression is significantly increased after rCDR internalization (125 ng/mL; D6; n E = 21) and can be i blocked by co-treatment with calpain antagonist MDL28170 (125 ng/mL + 10 μM MDL28170; n E = 5). Calpain antagonist MDL28170 reduced the CDR-induced CB + and L7/Pcp-2 + PC loss. d z-Stack multiphoton micrographs: cotreatment with calpain antagonist MDL28170 (10 μM) beneficially affects PC anti-CB (magenta) staining after hCDR2/2L +(PS3) internalization (4 μL/mL, 6 days); scale bars 40 μm. Stereological counting of CB + (e) and L7/Pcp-2 + (f) cells/mm 3 in these micrographs showed that hCDR2/2L +(PS3) /MDL28170 treatment (5, 10, 20 μM) reduced the CDR-induced loss of CB [n E = 6 (PS3) and n E = 4 (PS4)] and L7/Pcp-2 [n E = 3 (PS4)]. g Similar observation was found for rCDR/MDL28170 co-treatment (125 ng/mL, 10 μM MDL28170, CB: n E = 5). Calpain antagonist reduced the CDR-induced loss depending on the CDR target to up to 60 % (Table 1 ). This was most pronounced for CDR2. j MAP kinase antagonist U0126 (5 μM) does not influence the loss of CB + or L7/Pcp-2 + PCs after hCDR2/2L +(PS3) internalization (1 μL/mL; 6 days; n E = 4). Data are mean ± SEM. Non-parametric two-tailed paired Mann-Whitney's U test. *p < 0.05; **p < 0.01; ***p < 0.001; # p < 0.008. OTSC can be used to study neurochemical, structural, and physiological changes linked to diseased in vivo brains [13, 44] . Hence, we created an ex vivo antibody-mediated PCD model by applying CDR-positive patients' sera and affinity-purified rabbit CDRs to the culture medium of cerebellar rat OTSC. These slices offer unique advantages because the tissue architecture is preserved, synaptic circuitries are maintained, and various treatments can be evaluated without the influence of activated immune cells and the bloodbrain barrier (BBB) [13, 21, [42] [43] [44] . The mechanisms of autoimmunity in paraneoplastic neurological diseases are complex and not yet understood. It is suggested that brain epitope-specific serum Abs can access the brain only if the integrity of the BBB is compromised [18, 20] . However, brain epitope-specific cerebrospinal fluid Abs can be produced by intrathecal synthesis due to activated T and B cells that can cross the BBB [51, 62] . Data from antiYo/CDR2-Ab positive PCD patients are contradictory in terms of cytotoxic T cell involvement [2, 3, 10, 56, 61, 65] . Therefore, it is of interest that PCs can internalize IgGs and that anti-Yo Abs can lead to cell injury and non-apoptotic death without the influence of activated immune cells [31, 33] .
Here, we demonstrate that both hCDR and rCDR can cause similar PC pathology. By using rCDR we exclude cytotoxic T cell involvement, since the cOTSC was not exposed to related peptides which could activate brainnaive resident T cells [42] . Therefore, our data are most likely immune cell independent. We found that both CDR2 -buffering activity of calbindin D 28K , (3) modify the VGCC modulator L7/Pcp-2, and (4) cause increase protein levels of VGCC and PKC. These events dramatically increase the levels of unbound cytoplasmic Ca 2+ to the millimolar range and thereby induce over-activation of calpain-2. (5) It is known that calpain over-activation causes rapid modifications of synaptic membrane-associated proteins (VGCC, AMPAR), cytoskeleton proteins, major postsynaptic density scaffolding proteins, and synaptic protein kinases (PKC) and phosphatases.
To prevent the enhanced Ca 2+ influx through VGCC and free the CB binding capability by lowering the unbound cytoplasmic Ca 2+ could be a putative neuroprotective treatment strategy. Antagonists to VGCC (ω-agatoxin), AMPA receptor (CNQX), PKCγ (K252a) and calpain (MDL28170) showed satisfactory neuroprotective impacts. Our data suggest that CDR2 are more likely interacting with cytosolic components and therefore responsible for calpain activation (K252a and MDL28170 treatment), whereas CDR2L are more likely to modify the postsynaptic density structure and physiology (ω-agatoxin and CNQX treatment). Therefore, both CDR antibodies can cause fatal alterations in the Purkinje cell signaling pathways and membrane structures by affecting actin remodeling, membrane reorganization, and protein trafficking, thereby cause neurodegeneration and CDR2L are internalized independently and their removal can partly reverse the calpain-2-dependent, but caspase-3-independent, pathology. We found equal effects of CDR2 and CDR2L on PC survival, although only a combination of CDR2/2L is associated with PCD [22] . However, CDR2/2L pathology was stronger, e.g., PKCγ results, and reciprocal Co-IP showed a CDR2-CDR2L complex in PCs, which supports the hypothesis that increased Ab avidity enhances the pathological effects [71] . Our CDR-induced pathology followed a similar time frame as described by Greenlee and colleagues [31] , but the CDR internalization mechanisms remain to be explored. A recent study by Congdon et al. [14] demonstrated antibody internalization via IgG-FcγII receptor endocytosis. IgG-FcγII receptors are found in PC and regulate cerebellar function [47] .
CDR internalization affects postsynaptic signaling and thereby Ca 2+ homeostasis: AMPAR-VGCC-PKCcalpain
In Fig. 9 we show the complexity, by which h/rCDR internalization changes PC physiology by targeting postsynaptic signaling factors and thereby modifies Ca 2+ homeostasis. We described these factors along with related neurological diseases in Table S1 . We found that the immunoreactivity of Ca 2+ homeostasis regulator CB and VGCC modulator L7/Pcp-2 was reduced. These proteins are functionally linked, since CB shapes the post-tetanic potentiation induced by the Ca 2+ influx through AMPAR and VGCC and can act as an activity-dependent sensor [32, 57] . When endogenous CB levels are reduced, PC dendritic outgrowth and differentiation is inhibited, and motor coordination and sensory integration fail [1, 4, 37, 74] . We found that the total CB protein levels are not affected by CDR internalization. However, Co-IP reveals that CDR2-CB forms a strong protein complex and therefore CDR2 antibody binding to CDR2 protein in the cell may disrupt CB function by sequestering CDR2 and thus hijacking CB's interacting partner. "CDR antibody washout" restored the CB immunoreactivity only partially, indicating irreversible modifications of the CB Ca 2+ -binding mechanism or protein structure, as seen in other neurodegenerative diseases [11, 50] .
CB dysfunction or deletion can result in drastic fast intracellular Ca 2+ -transient elevation which greatly influences Ca 2+ homeostasis [4] . In PC signaling, intracellular Ca 2+ microdomain variations due to AMPAR, VGCC, or PKC activity play a crucial role [24, 27, 34, 57, 68] . AMPAR activation by glutamate binding and site-specific PKC and receptor tyrosine kinases' phosphorylation provides the depolarization necessary for opening VGCCs and therefore increases Ca 2+ influx [19, 32, 57, 73] . We found that the P/Q-type VGCC modulator L7/Pcp-2 immunoreactivity is reduced and Cav2.1 (P/Q-type VGCC) protein concentration is increased by twofold after CDR internalization. L7/Pcp-2 modulates VGCC function in a concentration-dependent manner and enhances or dampens VGCC kinetics to shape fast Ca 2+ influx in synaptic Ca 2+ microdomains [39] . Inhibiting VGCC activity directly (ω-agatoxin) or indirectly (CNQX) prevented or reduced dramatically the CDR-induced CB and L7/Pcp-2 loss, respectively. CDR2L-induced pathology was more effectively reversed than CDR2 during AMPAR inhibition. Data from primary PC culture and synaptoneurosome preparation (data not shown) support that CDR2L is synaptic and could thereby be involved in membrane-associated signaling cascades. CB and L7/Pcp-2 dysfunction and VGCC up-regulation will promote excessive Ca 2+ influx into PCs, which can activate cell death pathways by enhancing PKC and Ca
2+
-dependent protease activity [41] . PKC is associated with apoptosis in ischemia and stroke [8, 29, 60] . In PCs, enhanced PKC activity will reduce dendritic differentiation, whereas reduced PKC activity increases it [45, 46] . We found that the up-regulation of PKCγ expression under CDR internalization was accompanied by reduced dendritic arborizations and loss of tertiary branches. In retina, L7/Pcp-2 interacts with PKC [64] and we found that the increased PKC activity led to reduced L7/Pcp-2 expression (data not shown). Inhibition of PKCγ activity prevented the CDR-induced morphological changes, the loss of CB as well as L7/Pcp-2 immunoreactivity and blocked the increased PKCγ protein expression. However, the increase in PKCγ expression was only seen for CDR2 and CDR2/2L, but not for CDR2L internalization, although K252a rescued the CB and L7/Pcp-2 immunoreactivity in all rCDR-treated cOTSCs. We therefore hypothesize that CDR internalization enhances PKC activity, which: first, reduces L7/Pcp-2 expression; second, increases Cav2.1 expression; third, increases intracellular Ca 2+ , which activates Ca 2+ -dependent proteases such as calpain-1 and calpain-2 and thereby induces neuronal death.
Calpain-1 and calpain-2 are activated by different cellular Ca 2+ concentrations. In Alzheimer's, Huntington's, and Parkinson's disease, calpain over-activation or dysregulation triggers neuronal death by truncation of important synaptic substrates [5, 16, 17, 26, 53, 59] . Western blot analysis revealed that CDR internalization significantly increased calpain-2 protein expression, but not calpain-1 which indicates a intracellular Ca 2+ level above 0.250 mM [75] . Inhibiting calpain activity by calpain antagonist MDL28170 reduced the CDR-induced CB loss and blocked calpain-2 protein enhancement. Interestingly, the CDR2L induced pathology is less affected by calpain inhibition than CDR2. This may be explained by the distribution of CDR2 (cytosol) and CDR2L (membrane) proteins [22] .
We hypothesize that CDR internalization affects activitydependent modifications of synaptic integrity, stability, and function of target proteins, which modulates the synaptic Ca 2+ transient by mediating over-activation of calpain-2 [5, 17] . As calpain-mediated truncation of substrates is regulated by their phosphorylation state, there is a possibility of cross talk between calpain activation and activation of mitogen-activated protein (MAP) kinase. MAP kinase signaling cascades are associated with PKC-dependent synaptic depression and declustering of receptors, inflammation, death receptors' activation, apoptosis, and oxidative stress [12, 23, 35] . Althought PKC inhibition prevented CDRinduced CB and L7/Pcp-2 loss, blockage of MAP kinase activity did not show any rescue effects.
Conclusion
PCD pathogenesis is largely unknown. We propose a twostep pathology mechanism. First, internalization of CDR antibodies modifies important regulatory factors of Ca 2+ homeostasis, which lead to the silencing of the PCs. Second, cytototoxic T cells and microglia mediate the clearing of diseased cells, as known from autopsy studies [61] .
CDR antibodies play an important role in the PCD pathogenesis by inducing PC loss, which causes severe ataxia, dysarthria, diplopia, and vertigo in PCD patients. In line with previous results, we have shown that such cerebellar findings can be linked to imbalance in intracellular Ca 2+ homeostasis due to alterations of CB, VGCC, or PKC [1, 27, 40, 58, 69] . Therefore, lowering the intracellular Ca 2+ levels by inhibition, the VGCC-AMPAR-PKC signaling pathway (Fig. 9 ) during the progress of PCD will beneficially modulate Ca 2+ homeostasis by stabilizing the Ca 2+ -binding capability of CB and prevent the induction of the critical calpain response cascade. The strong neuroprotective effect of antagonizing VGCC-AMPAR-PKC signaling pathway during CDR antibody internalization may therefore be of potential clinical relevance.
